UPDATE: Citi Downgrades Biogen (BIIB) to Neutral
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.83 -0.39%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - June 12, 2013 7:37 AM EDT)
Citi downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral. Analyst Yaron Werber said Tecfidera may not get regulatory data protection (RDP) in Europe. Werber's comments follow talks with European regulatory experts.
Werber noted that Tecfidera's U.S. introduction was solid, but he thinks prescriptions might be overstated by 31%.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $223.03 yesterday.
Citi downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral. Analyst Yaron Werber said Tecfidera may not get regulatory data protection (RDP) in Europe. Werber's comments follow talks with European regulatory experts.
Werber noted that Tecfidera's U.S. introduction was solid, but he thinks prescriptions might be overstated by 31%.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $223.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Freedom Broker Double Downgrades Mosaic (MOS) to Sell
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Downgrades, Hot DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
